Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia

NCT02932605 is registered in ClinicalTrials.gov with UMC Utrecht as lead sponsor.

NCT NCT02932605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02932605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia
Lead sponsor
UMC Utrecht
Phase
Not applicable
Overall status
Completed
Start date
November 3, 2017
Completion date
January 31, 2020
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia